Will US-Danish relations deteriorate further and permanently, negatively impact, trade, security, and the whole notion of the West as we know it? The short answer is, “Hopefully not!”. But hope is not ...
Ancient DNA is telling us more and more about humans and environments long past. Could it also help rescue the future?
EDEN's concentrated portfolio, with the top 5 holdings making up 42% of the fund, allows for easier tracking and potential ...
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry. The Danish pharma giant ...
Last week, Novo Nordisk released its year-end results, including how it performed over the last three months of 2024. Net sales for the quarter totaled 85.7 billion Danish kroner ($12 billion) and ...
Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling ...
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results